 NEWARK, Calif., Sept. 06, 2022 GLOBE NEWSWIRE -- CymaBay Therapeutics, Inc. NASDAQ: CBAY, a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. 